FDA approves Telix’s Pixclara for glioma imaging as shares jump 7.44%
AI Summary- FDA approved Telix Pharmaceuticals’ Pixclara for glioma imaging.
- 7.44%: Telix shares rose to $12.13 on Monday.
- Pixclara is undergoing a Phase 3 study for potential brain-metastasis diagnosis.